Biochemically Recurrent Prostate Carcinoma

Oncology·MeSH: Prostatic Neoplasms

12 drugs in development·3 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(9)

Drug	Company
degarelix	GH Research PLC (GHRS)
goserelin	GH Research PLC (GHRS)
goserelin	GH Research PLC (GHRS)
leuprolide	GH Research PLC (GHRS)
leuprolide	GH Research PLC (GHRS)
Relugolix	Myovant Sciences Ltd. (MYOV)
Relugolix Combination Tablet	Myovant Sciences Ltd. (MYOV)
triptorelin	GH Research PLC (GHRS)
triptorelin	GH Research PLC (GHRS)

Phase 2(2)

Drug	Company
Leuprolide	ENANTA PHARMACEUTICALS INC (ENTA)
Relugolix	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(1)

Drug	Company
Leuprolide	Myovant Sciences Ltd. (MYOV)

BioSniper tracks 12 drugs in development for Biochemically Recurrent Prostate Carcinoma across 3 companies.

There are 3 clinical trials targeting Biochemically Recurrent Prostate Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.